Jeevan Scientific Technology Limited has successfully completed its Rs 30.74 crore capital raising plan through the allotment of convertible warrants and equity shares. The company's board meeting held on January 2, 2026, approved the allotment of securities to promoters and non-promoters following BSE's in-principle approval.

Major Stake Acquisition by Padmaja Private Trust

In a significant development, Padmaja Private Trust has acquired a substantial 7.53% stake in the company through the recent preferential allotment. The acquisition details are as follows:

This acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as Padmaja Private Trust crossed the substantial acquisition threshold.

SEBI Regulatory Compliance

Following the acquisition, Padmaja Private Trust has filed the mandatory disclosure under Regulation 29(1) of SEBI regulations on January 5, 2026. The filing confirms the acquisition details and provides comprehensive information about the trust's holdings:

Complete Allotment Details

The board has successfully allotted the planned securities as outlined in their earlier proposal:

The allotment was completed pursuant to BSE's in-principle approval granted through Letter Reference No. LOD/PREF/HC/FIP/1377/2025-26 dated December 18, 2025.

Updated Capital Structure

Following the allotment, the company's equity capital structure has been revised:

Fund Utilization and Strategic Plans

The funds raised will be utilized for:

This successful capital raise and the entry of Padmaja Private Trust as a substantial investor strengthens Jeevan Scientific Technology's financial position and provides the necessary resources for its planned expansion in the healthcare sector, including potential acquisitions and capacity enhancement initiatives.

Jeevan Scientific Technology has received multiple SEBI disclosure filings from four promoters regarding the acquisition of 30,00,000 convertible warrants through preferential allotment. All transactions were completed on January 2, with disclosures filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Warrant Acquisition Details

Four promoters of the company acquired convertible warrants through preferential issue, representing a coordinated strategic move to increase their stakes through convertible instruments. Krishna Kishore Kuchipudi, Managing Director, led the acquisitions with the largest warrant holding.

Individual Shareholding Changes

The acquisitions have resulted in significant changes to each promoter's overall shareholding pattern in the company. While equity shareholdings remain unchanged, the addition of convertible warrants substantially increases their potential diluted stakes.

Share Capital Structure Impact

The preferential allotment of convertible warrants significantly affects the company's potential diluted share capital structure. The company's equity capital has increased from ₹15.83 crores to ₹19.92 crores, with substantial potential for further expansion upon warrant conversion.

Regulatory Compliance

All disclosures confirm that the acquirers belong to the promoter group of Jeevan Scientific Technology Limited. The filings were submitted to BSE Limited, where the company's shares are listed under scrip code 538837. All regulatory requirements under SEBI takeover regulations have been fulfilled through these comprehensive disclosures, ensuring transparency in the substantial acquisition of convertible instruments by the promoter group.